Hope Rugo: Important work on HR+ disease by Laura Huppert
Hope Rugo, Professor of medicine at the University of California San Francisco, shared an article on X:
“Congratulations Laura Huppert!
Important work HR+ disease. pCR rates for patients with HR+/HER2- high-risk, EBC by clinical and molecular features in the phase II I-SPY2 clinical trial – Annals of Oncology.”
Authors: Laura Huppert, et al.
Dr. Hope Rugo, is a professor of medicine at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. With experience in hematology and oncology, she specializes in breast cancer treatment and clinical trials. Dr. Rugo’s research focuses on innovative therapies and combination treatments to improve outcomes for breast cancer patients, including immunotherapy and targeted agents. She is known for her contributions to reducing treatment toxicity educating through initiatives like the Breast Forum.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023